Propanc Biopharma Provides Shareholder Update and Plans to Enter Clinical Development Stage with Lead Cancer Treatment Candidate

Propanc Biopharma, a biopharmaceutical company focused on developing novel cancer treatments for patients with recurring and metastatic cancer, has announced that it is entering into a transformational stage as it prepares to file a Form 10-K annual report. The report will include recent developments and forecast for 2023/24. Propanc's lead product candidate PRP targets and eradicates cancer ste..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 23.
  • textsms

AstraZeneca and Quell to Develop Cell Therapies in $2B Deal for Type 1 Diabetes and IBD

AstraZeneca has teamed up with Quell Therapeutics to develop therapies for Type 1 diabetes and inflammatory bowel disorder, potentially putting over $2 billion on the line. AstraZeneca provided $85 million to get started, while the rest of the opportunity comes in the form of development and commercialization milestones and potential royalties down the line. Quell will be responsible for develop..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms